Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer

Volume: 46, Issue: 2, Pages: 100793 - 100793
Published: Apr 1, 2022
Abstract
For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and...
Paper Details
Title
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
Published Date
Apr 1, 2022
Volume
46
Issue
2
Pages
100793 - 100793
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.